2026-08-13 Otsuka Holdings Co.,Ltd. “In an interim analysis of the Phase III REZILIENT3 trial in the group receiving diparereltinib in combination with chemotherapy for first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, the primary endpoint of progression-free survival was achieved.”